Swiss Pharma Industry Braces for US Trade Scrutiny

The threat stems from Section 301 investigations, a mechanism the U.S. uses to challenge suspected unfair trade practices. Republican lawmakers recently pressed the U.S. Trade Representative and the commerce secretary to open formal probes, explicitly accusing both Germany and Switzerland of forcing American consumers to shoulder the financial burden of global pharmaceutical innovation. These legislators argue that foreign governments are effectively free-riding on the U.S. market by capping spending on life-saving drugs.

For Switzerland, the stakes are exceptionally high. Pharmaceutical and chemical products accounted for more than half of the country’s total exports last year, with giants like Roche and Novartis serving as the pillars of the national economy. The government is currently reviewing measures to reduce mandatory healthcare prices, a policy shift that industry leaders argue will invite retaliatory tariffs. While Germany recently faced similar pressure, Berlin has shown signs of backtracking on its healthcare overhaul in response to the looming threat of U.S. trade sanctions.